A Phase I/II, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study of Sevuparin/DF02, as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria

Trial Profile

A Phase I/II, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study of Sevuparin/DF02, as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Sevuparin (Primary) ; Atovaquone/proguanil
  • Indications Falciparum malaria
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Modus Therapeutics
  • Most Recent Events

    • 28 Nov 2014 According to Dilaforette media release, results were presented at the American Society of Tropical Medicine and Hygiene (ASTMH) meeting.
    • 18 Aug 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 08 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top